Up to 45% of dementia risk can be prevented or delayed: WHO

Up to 45 percent of dementia risk could be prevented or delayed through the management of modifiable lifestyle and health factors, according to new guidelines released by the World Health Organization on Wednesday, 15 July 2026. This announcement reflects a significant expansion of the agency's previous recommendations, first issued in 2019, as the evidence base regarding cognitive health has grown.

Dementia, a condition characterized by brain diseases that affect memory, thinking, and daily functioning, affects more than 57 million people worldwide. With nearly 10 million new diagnoses occurring annually, the condition serves as a major cause of disability and dependency, and is currently the seventh leading cause of death globally. Alzheimer’s disease remains the most prevalent form of the condition, accounting for an estimated 60 to 70 percent of all cases.

Related imagery

The updated Who guidance emphasizes that dementia is not an inevitable aspect of aging. Health systems and individuals have an opportunity to significantly reduce the global economic burden of the condition, which is estimated at $1.3 trillion each year. Roughly half of this total financial cost stems from unpaid care provided by friends and family members.

Recommended Interventions

The WHO guidelines categorize risk-reduction strategies into several domains, including environmental exposure, lifestyle choices, and the management of medical conditions. The agency recommends that individuals and policymakers prioritize the following actions:

• Reducing exposure to air pollution.
• Quitting tobacco use and limiting alcohol consumption.
• Increasing physical activity and maintaining a healthy diet.
• Engaging in cognitive training, mental stimulation, and regular social activities for adults with normal cognition or those experiencing mild cognitive impairment.
• Managing conditions such as high blood pressure, diabetes, and high cholesterol.
• Considering hearing aids as a strategy for those experiencing hearing loss.

In a departure from some self-care practices, the WHO explicitly advises against the routine use of vitamin B, vitamin E, omega-3 fatty acids, or multivitamin supplements for the sole purpose of preventing dementia. The agency cites a lack of evidence for clinical benefit and the possibility of potential, unexpected harm when no specific nutritional deficiency has been diagnosed.

Emerging Diagnostic and Therapeutic Frontiers

While the WHO focuses on broad preventative strategies, researchers continue to explore biological interventions. At the Alzheimer’s Association International Conference held in London, scientists presented data on the role of tau proteins—which accumulate as abnormal tangles within brain cells—as a primary target for future therapies. An experimental drug, diranersen, which works by inhibiting the production of tau at the genetic source, showed a 50 to 65 percent reduction in tau levels in a study of 416 participants. This reduction was associated with a slowing of cognitive decline by up to 50 percent on specific memory and reasoning tests.

Diagnostics are also evolving to identify risk earlier in the life course. A study published in JAMA by researchers at Mass General Brigham and Harvard Medical School suggests that blood-based tests measuring a form of tau known as ptau217 may predict a higher likelihood of cognitive impairment up to 10 years before symptoms manifest. In a group of over 2,700 cognitively normal participants, those with the highest ptau217 levels were 78 percent more likely to become cognitively impaired within a decade.

Clinical and Policy Disagreements

Despite these technological advances, the medical community maintains differing perspectives on the most effective path forward. Some experts argue that tau is a vital protein for maintaining the architecture of neurons, and that targeting it requires precision to avoid affecting normal function. Conversely, others maintain that tau becomes an enabler of disease once abnormal processes begin, making its reduction the most pragmatic therapeutic strategy.

Furthermore, structural barriers to care remain. Currently, screening for asymptomatic individuals is not covered by major insurers or Medicare, as the U.S. Preventive Services Task Force previously found insufficient evidence to support general population screening. Industry groups, including the Alzheimer’s Association, are working to develop the necessary evidentiary foundation to support potential coverage for these advanced screening methods.

What to Watch Next

• Integrated Care: Efforts by national health systems to embed brain health, mental health, and noncommunicable disease services into primary care.
• Regulatory and Coverage Decisions: Potential policy shifts from insurance providers and Medicare regarding the funding of blood-based tau screening.
• Clinical Trials: Longitudinal studies to determine if the benefits of anti-tau drugs like diranersen persist over time and whether combined treatments with existing anti-amyloid therapies might lead to stabilized cognitive function.